CORRECTIONS

Author Corrections

The June 10, 2011, original report by Freedman et al, entitled “Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older” (J Clin Oncol 29:2327-2333, 2011), contained an error.

The second to last sentence of the caption for Figure 3 was given as: “For example, in this table, among 10,000 black women with a uterus, age 50 to 59 years, and with a 5-year IBC risk of 3.5%, one expects that 62 life-threatening equivalent events would be prevented in 5 years by taking raloxifene instead of placebo, and there is moderate evidence ($P \geq 6$

but < 0.9 ; gold) that the benefits of taking raloxifene outweigh the risks.”

While it should have been:

“For example, in this table, among 10,000 black women with a uterus, age 50 to 59 years, and with a 5-year IBC risk of 3.5%, one expects that 62 life-threatening equivalent events would be prevented in 5 years by taking raloxifene instead of placebo, and there is moderate evidence ($P \geq 0.6$ but < 0.9 ; gold) that the benefits of taking raloxifene outweigh the risks.”

The authors apologize for the mistake

DOI: 10.1200/JCO.2013.53.9015; published November 10, 2013

The July 10, 2013, article by Ward et al, entitled “Population-Based Molecular Screening for Lynch Syndrome: Implications for Personalized Medicine” (J Clin Oncol 31:2554-2562, 2013), contained an error.

In Table 4, the nucleotide change in gene MLH1 for the patient aged 44.7 years was given as “c.[1-?_227+?del] + [=].” It should have been “c.[1-?_2271+?del] + [=].” The authors apologize for the mistake

DOI: 10.1200/JCO.2013.53.9056; published November 10, 2013

Journal Correction

The October 10, 2013, article by Yin et al, entitled “Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study” (J Clin Oncol 31:3647-3655, 2013), contained an error.

In Figure 1, a group under Analysis in the Non-randomly assigned arm was labeled as “Antiviral group (n = 402)”, whereas it should have been “**Control group** (n = 402)”.

Journal of Clinical Oncology apologizes for the mistake.

DOI: 10.1200/JCO.2013.53.8991; published November 10, 2013